^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

IFNG expression

i
Other names: IFNG , Interferon gamma
Entrez ID:
Related biomarkers:
20d
Transcriptome analysis of immune-inflammatory regulation in Tremella fuciformis-derived polysaccharide reeducated B16 cells: A subcutaneous model. (PubMed, Adv Clin Exp Med)
B16 cells subcutaneously exposed to TFP in mice induced an immune and inflammatory response to inhibit tumors. The study of the function of TFP-reeducated B16 cells to improve cancer immunotherapy may be of particular research interest. This approach could be an alternative and more efficient strategy to deliver cytokines and open up new possibilities for long-lasting, multi-level tumor control.
Journal • IO biomarker
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL17A (Interleukin 17A) • IL1B (Interleukin 1, beta)
|
IFNG expression
24d
Trichostatin A-modified vaccine provides superior protection against ovarian cancer formation and development. (PubMed, Braz J Med Biol Res)
This tumor vaccine therapy may increase antigen exposure, synergistically activate the immune system, and ultimately improve remission rates. A vaccine strategy designed to induce effective tumor immune response is being considered for cancer immunotherapy.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CD4 (CD4 Molecule) • CSF2 (Colony stimulating factor 2) • IL17A (Interleukin 17A) • IL4 (Interleukin 4) • IL7 (Interleukin 7)
|
IFNG expression • VEGFA expression
|
trichostatin A (VTR-297)
28d
TGF β1 promotes the polarization of M2-type macrophages and activates PI3K/mTOR signaling pathway by inhibiting ISG20 to sensitize ovarian cancer to cisplatin. (PubMed, Int Immunopharmacol)
In conclusion, our study highlights the critical role played by ISG20 within the network underlying cisplatin resistance in ovarian cancer. Targeting ISG20 using IFN-γ or TGF-β1 inhibitors may represent a promising therapeutic strategy for treating ovarian cancer.
Journal
|
IFNG (Interferon, gamma) • TGFB1 (Transforming Growth Factor Beta 1)
|
IFNG expression
|
cisplatin
28d
Keratinocytes present Staphylococcus aureus enterotoxins and promote malignant and non-malignant T cell proliferation in cutaneous T cell lymphoma. (PubMed, J Invest Dermatol)
In conclusion, we show that, upon exposure to patient-derived S. aureus and SE, keratinocytes stimulate IL-2Rγ/JAK3-dependent proliferation of malignant and non-malignant T-cells in an environment with non-malignant T-cells. These findings suggest that keratinocytes in the TME play a key role in S. aureus mediated disease activity in CTCL.
Journal
|
IFNG (Interferon, gamma) • IL2 (Interleukin 2) • JAK3 (Janus Kinase 3)
|
IFNG expression • JAK3 mutation
28d
Neurobrucellosis (Brucella ceti) in striped dolphins (Stenella coeruleoalba): Immunohistochemical studies on immune response and neuroinflammation. (PubMed, Vet Pathol)
Our results showed that the inflammation and neuroinflammation in neurobrucellosis of striped dolphins mimic human neurobrucellosis and in vitro and in vivo studies in laboratory animals. Cetacean disease surveillance can be exploited to expand the knowledge of the pathogenesis and immunology of infectious diseases, particularly brucellosis, under a One Health approach.
Journal
|
CD20 (Membrane Spanning 4-Domains A1) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • FAP (Fibroblast activation protein, alpha) • GFAP (Glial Fibrillary Acidic Protein)
|
IFNG expression • IL2 expression
29d
IFN-α/β/IFN-γ/IL-15 pathways identify GBP1-expressing tumors with an immune-responsive phenotype. (PubMed, Clin Exp Med)
Functionally, GBP1 was mainly expressed in macrophages and strongly correlated with chemokines involved in T-cell migration. Therefore, our study comprehensively investigated the potential role of GBP1 in immunotherapy, which could serve as a novel biomarker for immunotherapy and a target for drug development.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • GBP1 (Guanylate Binding Protein 1) • IFNA1 (Interferon Alpha 1) • IL15 (Interleukin 15)
|
IFNG expression
30d
Pretreatment with inflammatory factors altered the secretome of human amniotic epithelial cells. (PubMed, Tissue Eng Part C Methods)
The target genes of upregulated exosomal miRNAs substantially contributed to the response to stimulus, metabolic pathways and PI3K-Akt signaling pathway. Our findings improve our understanding of the biological characteristics of hAECs after proinflammatory factor pretreatment and provide novel insights to strengthen and optimize the therapeutic potential of hAECs and their secretome in regenerative medicine.
Journal
|
IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha)
|
IFNG expression
30d
Upregulation of Immune checkpoint PD-L1 in Colon cancer cell lines and activation of T cells by Leuconostoc mesenteroides. (PubMed, World J Microbiol Biotechnol)
mesenteroides existing enhances T cells viability and activity. GPCR41/42 is a possible link between L. mesenteroides, YAP-1 and PD-L1.
Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • IFNG (Interferon, gamma) • YAP1 (Yes associated protein 1) • IL2 (Interleukin 2) • TLR2 (Toll Like Receptor 2)
|
PD-L1 expression • IFNG expression
30d
Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma. (PubMed, Sci Rep)
Our validation cohort confirmed the prognostic power of hypoalbuminemia for OS (HR = 1.98, 95% CI 1.16-3.38; Cox P = 0.0127) and was complementary to serum LDH in analyses for both OS (LDH-adjusted HR = 2.12, 95% CI 1.2-3.72, Cox P = 0.00925) and PFS (LDH-adjusted HR = 1.91, 95% CI 1.08-3.38, Cox P = 0.0261). In conclusion, pretreatment hypoalbuminemia was a powerful predictor of outcome in ICI in melanoma and showed remarkable complementarity to previously established biomarkers, including high LDH.
Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Metastases
|
IFNG (Interferon, gamma)
|
IFNG expression
1m
Correlation of High-Grade Osteosarcoma Response to Chemotherapy with Enhanced Tissue Immunological Response: Analysis of CD95R, IFN-γ, Catalase, Hsp70, and VEGF. (PubMed, Virchows Arch)
VEGF expression in macrophages was significantly higher in the good response group. In conclusion, this study enhances our understanding of immune-chemotherapy interactions in osteosarcoma and identifies potential biomarkers for targeted interventions.
Journal
|
IFNG (Interferon, gamma) • FAS (Fas cell surface death receptor) • CAT (Catalase)
|
IFNG expression • VEGFA expression
1m
CD3, CD8, IFN-γ, tumor and stroma inflammatory cells as prognostic indicators for surgically resected SCLC: evidences from a 10-year retrospective study and immunohistochemical analysis. (PubMed, Clin Exp Med)
Complete postoperative adjuvant therapy remains an independent factor promoting a better prognosis for SCLC patients undergoing surgical resection. Moreover, CD3, CD8, IFN-γ, TIC, and SIC may serve as potential indicators for predicting the prognosis of surgically resected SCLC.
Retrospective data • Journal • Stroma • Inflammatory cell
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma)
|
IFNG expression
1m
Prognostic biomarkers in melanoma: a 2023 update from clinical trials in different therapeutic scenarios. (PubMed, Expert Rev Mol Diagn)
Future research should prioritize large-scale, prospective studies to validate and standardize these biomarkers, emphasizing clinical relevance and real-world applicability. Easily accessible biomarkers have the potential to enhance the precision and effectiveness of melanoma management.
Review • Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • IFNG (Interferon, gamma)
|
PD-L1 expression • IFNG expression
1m
Glutamine promotes human CD8+ T cells and counteracts imiquimod-induced T cell hyporesponsiveness. (PubMed, iScience)
Finally, Gln was sufficient to promote IFN-γ-production in IMQ-treated T cells. Our findings indicate that Gln metabolism can be harnessed for treating KDSCs.
Journal • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • SLC1A5 (Solute Carrier Family 1 Member 5) • GZMB (Granzyme B)
|
CD8 expression • IFNG expression
|
Zyclara (imiquimod)
1m
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CD8 (cluster of differentiation 8) • CCND1 (Cyclin D1) • IFNG (Interferon, gamma) • IL10 (Interleukin 10) • GPX4 (Glutathione Peroxidase 4) • SLC7A11 (Solute Carrier Family 7 Member 11)
|
PD-L1 expression • IFNG expression • GPX4 expression
1m
Single-cell sequencing of tumour infiltrating T cells efficiently identifies tumour-specific T cell receptors based on the T cell activation score. (PubMed, Cancer Immunol Immunother)
We found that all three TCRs in each patient could specifically identify corresponding ATCs. In conclusion, we established an efficient approach to isolate tumour-reactive TCRs based on combinations of multiple activation and effector molecules through single-cell RNA sequencing.
Journal • IO biomarker
|
IFNG (Interferon, gamma) • IL2RA (Interleukin 2 receptor, alpha) • CD69 (CD69 Molecule) • TNFRSF9 (TNF Receptor Superfamily Member 9) • GZMB (Granzyme B) • GZMA (Granzyme A) • GZMK (Granzyme K) • PRF1 (Perforin 1)
|
IFNG expression • IL2 expression
1m
NK cell transfer overcomes resistance to PD-(L)1 therapy in aged mice. (PubMed, Exp Hematol Oncol)
Our findings revealed the decreased sensitivity of elderly patients to immunotherapy, as well as in aged mice. This may be attributed to the reduction of NK cells in aged mice, which inhibits CD103+ DCs recruitment and its CD86 expression and ultimately leads to immunotherapy resistance.
Preclinical • Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • ITGAE (Integrin Subunit Alpha E) • CD86 (CD86 Molecule)
|
IFNG expression
1m
Esaxerenone Inhibits Interferon-γ Induced Pyroptosis of Macrophages in the Lungs of Aldosterone-treated Mice. (PubMed, Inflammation)
In addition, IFN-γ secreted by CD8+ T cells is associated with macrophage pyroptosis. In conclusion, the inhibition of macrophage pyroptosis can effectively alleviate lung injury.
Preclinical • Journal
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)
|
IFNG gene signature overexpression • IFNG expression
1m
Therapeutic ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB (clinicaltrials.gov)
P2, N=1500, Not yet recruiting, AIDS Clinical Trials Group | Trial completion date: Dec 2028 --> Apr 2029 | Initiation date: Apr 2024 --> Oct 2024 | Trial primary completion date: Dec 2028 --> Apr 2029
Trial completion date • Trial initiation date • Trial primary completion date
|
IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • IL2 (Interleukin 2)
|
IFNG expression
|
rifampicin
2ms
CBX3 antagonizes IFNγ/STAT1/PD-L1 axis to modulate colon inflammation and CRC chemosensitivity. (PubMed, EMBO Mol Med)
Strikingly, CBX3 deletion heightened CRC cells sensitivity to IFNγ, which ultimately enhanced their chemosensitivity under IFNγ stimulation in vitro with CRC cells and in vivo with a syngeneic mouse tumor model. Overall, this work reveals that by negatively tuning IFNγ-stimulated immune genes' transcription, CBX3 participates in modulating colon inflammatory response and CRC chemo-resistance.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • IFNG (Interferon, gamma) • STAT1 (Signal Transducer And Activator Of Transcription 1) • CBX3 (Chromobox 3)
|
PD-L1 expression • IFNG expression
2ms
Short-chain fatty acids induced lung tumor cell death and increased peripheral blood CD4+ T cells in NSCLC and control patients ex vivo. (PubMed, Front Immunol)
Overall, this study highlights the potential of SB in inhibiting lung cancer cell growth, triggering apoptosis, inducing cell cycle arrest, and modulating immune responses by activating peripheral blood CD4+ T cells while selectively inducing IFN-γ-R1 in NK cells in peripheral blood and inhibiting peripheral blood CD8+ T cells and NK cells. Thus, understanding the mechanisms of action of SB in the TME and its influence on the immune system provide valuable insights of potentially considering SB as a candidate for adjunctive therapies in NSCLC.
Preclinical • Journal • Tumor cell
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule) • GZMB (Granzyme B) • THY1 (Thy-1 membrane glycoprotein)
|
IFNG expression
2ms
Non-canonical deubiquitination of OTUB1 induces IFNγ-mediated cell cycle arrest via regulation of p27 stability. (PubMed, Oncogene)
Src downregulation reduced OTUB1 and p27 expression, suggesting that IFNγ-induced cell cycle arrest is mediated by the Src-OTUB1-p27 signaling pathway. Our findings highlight the pivotal role of OTUB1 in IFNγ-induced p27 expression and cell cycle arrest, offering therapeutic implications.
Journal
|
IFNG (Interferon, gamma) • OTUB1 (OTU Deubiquitinase, Ubiquitin Aldehyde Binding 1)
|
IFNG expression • CDKN1B expression
2ms
Synergistic immunomodulatory effect of synbiotics pre- and postoperative resection of pancreatic ductal adenocarcinoma: a randomized controlled study. (PubMed, Cancer Immunol Immunother)
Administration of synbiotics and probiotics significantly decreased the rate of postoperative complications including anastomotic leakage, diarrhea, and abdominal distension (p = 0.032, p = 0.044, p = 0.042, respectively), with a remarkable reduction in bacteremia in the synbiotics group. These results revealed that this synbiotics formulation potentially enhances the immune response and reduces complications associated with surgery.Clinical trial identification: NCT06199752 (27-12-2023).
Clinical • Journal • Immunomodulating
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta)
|
CD8 expression • IFNG expression
2ms
TIM-3+ CD8 T cells with a terminally exhausted phenotype retain functional capacity in hematological malignancies. (PubMed, Sci Immunol)
Here, we characterize a TEX subset in hematological malignancies that paradoxically retains function and is distinct from dysfunctional TEX found in chronic viral infections. Thus, IFN-γ+ TPHEX represent a potential target for immunotherapy of blood cancers.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • PRF1 (Perforin 1) • BATF (Basic Leucine Zipper ATF-Like Transcription Factor)
|
IFNG expression
2ms
Clinical prognostic significance of xeroderma pigmentosum group C and IFN‑γ in non‑small cell lung cancer. (PubMed, Oncol Lett)
Additionally, high expression of both markers was associated with a favorable prognosis in patients with NSCLC. The aforementioned findings suggest that the expression of XPC and IFN-γ has prognostic value in clinical practice and is expected to become a marker for clinical application.
Journal
|
IFNG (Interferon, gamma) • XPC (XPC Complex Subunit, DNA Damage Recognition And Repair Factor)
|
IFNG expression
2ms
Prognostic Significance of Immune Cell Infiltration in Muscle-invasive Bladder Cancer Treated with Definitive Chemoradiation: A Secondary Analysis of RTOG 0524 and RTOG 0712. (PubMed, Eur Urol Oncol)
PATIENT SUMMARY: We analyzed patient samples from two clinical trials (NRG/RTOG 0524 and 0712) of chemoradiation for muscle-invasive bladder cancer using a novel method to assess immune cells in the tumor microenvironment. Higher expression of genes associated with immune activation and high overall immune-cell content were associated with better disease-free survival and overall survival for patients treated with chemoradiation.
Journal • IO biomarker • Immune cell
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IDO1 (Indoleamine 2,3-dioxygenase 1) • ICOS (Inducible T Cell Costimulator)
|
IDO1 expression • IFNG expression
2ms
Blockade of TGF-β and PD-L1 by bintrafusp alfa promotes survival in preclinical ovarian cancer models by promoting T effector and NK cell responses. (PubMed, Br J Cancer)
Our preclinical studies of BA in advanced ovarian cancer models support further testing of BA as an improved immunotherapy option for patients with advanced ovarian cancer.
Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TGFB1 (Transforming Growth Factor Beta 1)
|
PD-L1 expression • IFNG expression
|
bintrafusp alfa (M7824)
2ms
Characterization of tumoricidal activities mediated by a novel immune cell regimen composing interferon-producing killer dendritic cells and tumor-specific cytotoxic T lymphocytes. (PubMed, BMC Cancer)
Phyduxon-T, which is a combination of natural killer cells, dendritic cells, and TAA-specific CD8 T cells, may enhance the efficacy of cancer immunotherapy.
Journal • IO biomarker • Immune cell
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma)
|
IFNG expression
3ms
Modulating Cholesterol Metabolism via ACAT1 Knockdown Enhances Anti-B-Cell Lymphoma Activities of CD19-Specific Chimeric Antigen Receptor T Cells by Improving the Cell Activation and Proliferation. (PubMed, Cells)
Moreover, the knockdown of ACAT1 led to better anti-tumor efficacy of anti-CD19 CAR-T cells in the B-cell lymphoma mice model. Our study demonstrates novel CAR-T cells containing ACAT1 shRNA with improved efficacy compared to conventional anti-CD19-CAR-T cells in vitro and in vivo.
Journal • CAR T-Cell Therapy
|
IFNG (Interferon, gamma) • CD69 (CD69 Molecule) • LAMP1 (Lysosomal Associated Membrane Protein 1) • GZMB (Granzyme B) • ACAT1 (Acetyl-CoA Acetyltransferase 1)
|
CD19 expression • IFNG expression
3ms
Comparative immunohistochemical analysis of inflammatory cytokines in distinct subtypes of Sweet syndrome. (PubMed, Front Immunol)
Increased expression of IFN-γ together with IL-17 was also noted in almost all subtypes among non-AOID-associated SS. These results demonstrate that IFN-γ and IL-17 are implicated in immunopathology of all SS subtypes, including AOID-associated SS, despite the presence of anti-IFN-γ autoantibodies.
Journal
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL17A (Interleukin 17A)
|
IFNG expression
3ms
Adenosine Increases the Immunosuppressive Capacity of Cervical Cancer Cells by Increasing PD-L1 Expression and TGF-β Production through Its Interaction with A2AR/A2BR. (PubMed, Pharmaceuticals (Basel))
These results strongly suggest the presence of a feedback mechanism that involves the adenosinergic pathway, the production of TGF-β1, and the upregulation of PD-L1 expression in CeCa cells that suppresses the antitumor response of CTLs. The findings of this study suggest that this pathway may be clinically important and may be a therapeutic target.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • IL10 (Interleukin 10) • TGFB1 (Transforming Growth Factor Beta 1)
|
PD-L1 expression • PD-1 expression • IFNG expression
3ms
Implications of NLRP3 Suppression Using Glibenclamide and miR-223 against Colorectal Cancer. (PubMed, Pharmaceuticals (Basel))
Notably, neither gli nor WTmiR-223 effectively prevented sphere invasion. These data suggest that, while WTmiR-223 could have a better anticancer effect in CRC compared to gli, the sole usage of miR-223-mediated NLRP3 suppression may not be sufficient to prevent CRC metastasis.
Journal
|
IFNG (Interferon, gamma) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • BAX (BCL2-associated X protein) • IL18 (Interleukin 18) • IL1B (Interleukin 1, beta) • MIR223 (MicroRNA 223) • NLRP3 (NLR Family Pyrin Domain Containing 3) • ANXA5 (Annexin A5) • BECN1 (Beclin 1)
|
IFNG expression • BAX expression • CXCL10 expression
3ms
Molecular and Clinicopathological Biomarkers in the Neoadjuvant Treatment of Patients with Advanced Resectable Melanoma. (PubMed, Biomedicines)
Pathological response to neoadjuvant treatment is a biomarker of a favorable prognosis and surrogate endpoint for recurrence-free survival in clinical trials. Despite the reliability of these biomarkers, risk stratification and response prediction in the neoadjuvant setting are still unsatisfactory and represent a critical knowledge gap, limiting the development of optimized personalized strategies in everyday practice.
Review • Journal • Tumor mutational burden • IO biomarker • Metastases
|
TMB (Tumor Mutational Burden) • IFNG (Interferon, gamma)
|
IFNG expression
3ms
Uterine Commensal Peptostreptococcus Species Contribute to IDO1 Induction in Endometrial Cancer via Indoleacrylic Acid. (PubMed, Biomedicines)
The IAA, IDO1, and kynurenine/tryptophan ratios were all higher in EC tissue, and the M1/M2 ratio was lower. Our study sheds light on the link between IDO1 induction and uterine Peptostreptococcus dysbiosis and provides a potential rationale for the role of Peptostreptococcus species in immune tolerance induction in type I endometrial cancer.
Journal • IO biomarker
|
IFNG (Interferon, gamma) • IDO1 (Indoleamine 2,3-dioxygenase 1) • IL10 (Interleukin 10)
|
IDO1 expression • IFNG expression
3ms
Stigmasterol Exerts an Anti-Melanoma Property through Down-Regulation of Reactive Oxygen Species and Programmed Cell Death Ligand 1 in Melanoma Cells. (PubMed, Antioxidants (Basel))
STIG also reverses the up-regulation of PD-L1 and phosphorylated STAT1 levels augmented by cisplatin, and STIG enhances CD8(+) T-cell-mediated cell death against B16F10 cells. These findings represent the first evidence of pro-apoptotic activity of STIG on melanoma cells through the down-regulation of ROS and PD-L1 pathways. Therefore, STIG may be an effective candidate for melanoma immunotherapy.
Journal • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma)
|
PD-L1 expression • IFNG expression
|
cisplatin
3ms
The ω-3 polyunsaturated fatty acid docosahexaenoic acid enhances NK-cell antitumor effector functions. (PubMed, Cancer Immunol Res)
The PGC-1α inhibitor SR-18292 in vitro and NK cell-specific knockout of PGC-1α in mice reversed the antitumour effects of DHA. In summary, our findings broaden the current knowledge on how DHA supplementation protects against cancer growth from the perspective of immunomodulation by upregulating PGC-1α signalling-mediated mitochondrial OXPHOS activity in NK cells.
Journal
|
IFNG (Interferon, gamma) • LAMP1 (Lysosomal Associated Membrane Protein 1)
|
IFNG expression • LAMP1 expression
3ms
MAIT cells are associated with responsiveness to neoadjuvant immunotherapy in COPD-associated NSCLC. (PubMed, Cancer Med)
In patients with NSCLC and COPD, response to immunotherapy is associated with accumulation of CD8+ MAIT cells showing immune exhaustion. These findings may contribute to innovative approaches for immunotherapy targeting CD8+ MAIT cells.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD69 (CD69 Molecule) • GZMB (Granzyme B)
|
IFNG expression
3ms
the EXPOSITION Study (clinicaltrials.gov)
P=N/A, N=200, Not yet recruiting, University of Pavia
New trial
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • TGFB1 (Transforming Growth Factor Beta 1) • IL17A (Interleukin 17A) • IL1B (Interleukin 1, beta) • IL22 (Interleukin 22)
|
IFNG expression
3ms
IFN‑γ induces apoptosis in gemcitabine‑resistant pancreatic cancer cells. (PubMed, Mol Med Rep)
In conclusion, IFN‑γ exhibited antitumor immune properties by upregulating MRP and downregulating BCRP expression, reversing drug‑resistance gene expression, and reducing cell viability and migration, while promoting apoptosis in PANC‑1/GEM cells. IFN‑γ could potentially serve as a treatment option for patients with GEM‑resistant pancreatic cancer.
Journal
|
IFNG (Interferon, gamma)
|
IFNG expression
|
gemcitabine
3ms
Directing the migration of serum-free, ex vivo-expanded Vγ9Vδ2 T cells. (PubMed, Front Immunol)
To better understand the migration of these cells and possibly influence their migration, NSG mice were conditioned with agents to clear BM cellular compartments, i.e., busulfan or total body irradiation (TBI), or promote T-cell migration to inflamed BM, i.e., incomplete Freund's adjuvant (IFA), prior to administering γδ T cells...Using an established neuroblastoma NSG mouse model, we show that intratumorally-injected γMSCs increase the homing of γδ T cells to this tumor. These studies provide insight into the migration of serum-free, ex vivo-expanded Vγ9Vδ2 T cells in NSG mice, which is critical to understanding the fundamental properties of these cells.
Preclinical • Journal
|
IFNG (Interferon, gamma) • CCL2 (Chemokine (C-C motif) ligand 2) • CCR2 (C-C Motif Chemokine Receptor 2)
|
IFNG expression
|
busulfan • ET206
3ms
Interferon-γ in the tumor microenvironment promotes the expression of B7H4 in colorectal cancer cells, thereby inhibiting cytotoxic T cells. (PubMed, Sci Rep)
The clinical outcome of patients with CRC was negatively related to the high expression of B7H4 in cancer cells or low expression of CD8 in the microenvironment. Therefore, B7H4 is a biomarker of poor prognosis in CRC patients, and interference with the IFN-γ/IRF1/B7H4 axis might be a novel immunotherapeutic method to restore the cytotoxic killing of CRC cells.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1) • GZMB (Granzyme B) • IRF1 (Interferon Regulatory Factor 1)
|
CD8 expression • VTCN1 underexpression • IFNG expression • IRF1 expression
3ms
Tumor-activated IL-2 mRNA delivered by lipid nanoparticles for cancer immunotherapy. (PubMed, J Control Release)
Further evaluations indicated that the U-101-LNP/IL-2F mRNA group maintained proper levels of inflammatory factors without obvious alterations in liver and renal functions. Taken together, the U-101-LNP/IL-2F mRNA formulation demonstrated effective antitumor activity and safety, which suggests potential applicability in clinical immunotherapy.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL2RA (Interleukin 2 receptor, alpha) • MMP14 (Matrix Metallopeptidase 14)
|
IFNG expression • IL2 expression
3ms
Influence of Zika virus on the cytotoxicity, cell adhesion, apoptosis and inflammatory markers of glioblastoma cells. (PubMed, Oncol Lett)
These findings indicate that ZIKV infection could lead to reduced cell viability, elevated CD73 expression, improved cellular adherence, and higher rates of apoptosis in glioblastoma cells. Further studies are required to explore the potential use of ZIKV in the treatment of GBM.
Journal
|
IFNG (Interferon, gamma) • CD73 (5'-Nucleotidase Ecto) • NT5E (5'-Nucleotidase Ecto) • CD14 (CD14 Molecule) • IL4 (Interleukin 4)
|
IFNG expression • CD73 elevation • CD73 expression • IL5 elevation